Numab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Numab to receive R&D funding for the preclinical development of ND081 Kaken…
Numab to receive R&D funding for the preclinical development of ND081 Kaken…
Sign in to your account